We found that the combination of BK‐dependent antiangiogenic peptide (14‐MAP) and VEGF‐dependent antiangiogenic agent (Avastin) was the most efficient in reducing tumor growth in vivo. This evidence concerns the gene VEGFA and neoplasm.